Longeveron Reports Positive Phase 2b Clinical Trial Results for Laromestrocel in Aging-Related Frailty

Article summary

Longeveron's Phase 2b clinical trial of its investigational stem cell therapy, laromestrocel, met its primary endpoint by demonstrating significant improvement in physical function for patients with aging-related frailty.